Psychedelic Therapy for Depression
Zenodo (CERN European Organization for Nuclear Research) August 11, 2026 DOI: 10.5281/zenodo.21893915 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Mixed-methods study Peer reviewed |
|---|---|
| Topics | Depression Psychedelic-assisted therapy |
| Key points | Argues that regulatory, clinical, and infrastructural barriers currently prevent psychedelic therapy from entering mainstream hospital care, and proposes a practical roadmap for safe, ethical, and scalable implementation. |
Abstract
Depression affects over 280 million people worldwide and remains one of the leading causes of disability and suicide. Existing treatments such as SSRIs and traditional psychotherapy often fail to provide relief, especially for individuals with treatment‑resistant depression. Recent clinical trials suggest that psychedelic‑assisted therapy using psilocybin or MDMA may offer rapid and durable improvements in depressive symptoms. However, despite promising evidence, these treatments remain confined to research settings. This paper examines the regulatory, clinical, and infrastructural barriers preventing psychedelic therapy from entering mainstream hospital care. Through a mixed‑methods approach - including literature review, case studies, expert interviews, and systems mapping - this research outlines the requirements for safe, ethical, and scalable implementation. The goal is to provide a practical roadmap for hospitals, policymakers, and clinicians seeking to translate psychedelic research into accessible mental health treatment.